Fourth Quarter & Full Year Report 2021

NORDIC NANOVECTOR

Q4 2021

2021 Highlights

- 106 of a targeted 120 evaluable patients have been enrolled into the pivotal PARADIGME Phase 2b trial for Betalutin® as of 28 February 2022
    - Given the ongoing impact from the SARS-CoV-2 omicron variant on patient recruitment, the Company anticipates the preliminary three-month data readout from PARADIGME to be reported during H2'2022 as communicated on 7 January 2022
- Erik Skullerud appointed as Chief Executive Officer (CEO)
    - Mr Skullerud brings more than 25 years' experience in the biopharma industry including more than 15 years at Amgen, including as Marketing Director Europe Oncology/Hematology, and seven years at Bayer Pharma
    - He has launched numerous highly innovative products in therapeutic areas including oncology and haematology, and as a consultant he has worked with some of the world's top pharma and biotech companies as well as small, highly specialised start-ups on a wide range of projects
- Sandra Jonsson appointed as Chief Operating Officer
    - Dr Jonsson takes over from Marco Renoldi, who is retiring from the role but will remain as a consultant to the Company
    - Dr Jonsson is a results-driven international Life Science executive, with >15 years of cross-functional experience in global pharmaceutical and biotechnology companies. She joins Nordic Nanovector from Alexion Pharmaceuticals, where she was Senior Director, Commercial International
- Pierre Dodion MD appointed as Chief Medical Officer
    - Dr Dodion has over 30 years' experience in the biopharmaceutical industry, spent mostly in the oncology and haematology areas. He brings deep clinical development and medical affairs expertise and has provided strategic insight and overseen multiple clinical trials
- In November 2021, the Company hosted an R&D Day highlighting its vision and strategy for creating value from Betalutin® as well as through the development of exciting opportunities that leverage its deep expertise and experience in CD37 biology
- Nordic Nanovector announced its support for The Health Policy Partnership's initiative to improve readiness for the use of radioimmunotherapy and to facilitate appropriate integration of this innovative cancer treatment modality in lymphoma treatment
- The Company entered into a research collaboration with the University of Pennsylvania to generate a novel CD37-targeting CAR-T cell therapy approach as a potential treatment for patients with B-cell malignancies
    - Nordic Nanovector will have an option to license exclusive worldwide rights to any CD37-targeting CAR-T cells that result from the collaboration
- Successful Private Placement and oversubscribed Repair Offering completed in February and April, respectively, raised approximately NOK 422 million (USD 49.7 million) in gross proceeds

Post-period highlights

- In January 2022 Nordic Nanovector raised approximately NOK 250 million gross (approximately USD 28.4 million) from a private placement of new shares. The proceeds will be used to:
    - fund preparation of activities required for the regulatory filing of Betalutin® and pre-approval inspections

  - continue the preparatory activities for the confirmatory Phase 3 trial including production of clinical material
  - preparations for Betalutin® market launch, and
  - general corporate purposes.
- The proceeds together with existing cash resources are expected to ensure financing beyond the preliminary 3-month data readout from PARADIGME targeted for H2'2022 and for at least an additional three months into 2023 to enable the Company to maximize shareholder value from the PARADIGME clinical trial
- Following the successful private placement, Nordic Nanovector is undertaking a subsequent share offering with a subscription period that commenced on 28 February 2022 and ends at 16.30 hours CET on 11 March 2022

Erik Skullerud, Chief Executive Officer of Nordic Nanovector, commented: "It's been a productive year for the Company as we continued to drive PARADIGME recruitment, made key appointments, and hosted our R&D Day highlighting the vision and strategy for Betalutin® and our wider pipeline. Combined with the proceeds from our two private placements and a repair offering – raising NOK 672 million in total – this means we are beginning 2022 in a strong position to complete PARADIGME and deliver the three-month data readout later in the year, despite the delays imposed by the COVID-19 pandemic. We remain focussed on our goal of advancing Betalutin® to meet the need for a chemo-free, effective yet tolerable treatment for non-Hodgkin's lymphoma patients."

Key figures Nordic Nanovector Group

Amounts in MNOK (except earnings/loss per share)	Fourth Quarter		Full Year	
	2021	2020	2021	2020
Total revenues	0.0	0.0	0.0	0.0
Total operating expenses	133.1	106.8	442.4	434.2
Operating profit (loss)	-133.1	-106.8	-442.4	-434.2
Net financial items	-0.4	-3.5	2.3	18.0
Total comprehensive income (loss) for the period	**-134.1**	**-112.1**	**-441.7**	**-417.6**
Basic and diluted earnings (loss) per share	**-1.37**	**-1.39**	**-4.65**	**-5.99**
Number of employees	**40**	**36**	**40**	**36**
Net change in bank deposits, cash and equivalents	-91.8	-86.7	-16.3	-176.8
Cash and equivalents at beginning of period	369.5	380.7	294.0	470.8
Cash and equivalents at end of period	**277.7**	**294.0**	**277.7**	**294.0**

Operational review

Introduction

Nordic Nanovector is committed to developing and delivering the therapeutic potential of Betalutin® and other innovative CD37-targeted immunotherapies to patients to address their unmet medical needs across haematological cancers and immune diseases.

The company is developing its wholly owned lead product candidate Betalutin® (177Lu lilotomab satetraxetan) as a new, targeted, single agent and one-time treatment for patients with non-Hodgkin's lymphoma (NHL).

Betalutin® is a radioimmunotherapy that has been designed to offer a new chemotherapy-free treatment modality for NHL patients. Betalutin® targets the CD37 receptor on the surface of B-cell tumours, a validated and alternative target to CD20 upon which the current standard-of-care NHL therapies, such as rituximab (RTX), are focused.

There is a clear need for new treatment options in NHL as it has been reported that 40-60% of patients treated with an RTX-containing regimen either become refractory to anti-CD20 based therapy or develop resistance within five years[1].

The company is advancing Betalutin® in PARADIGME, a global pivotal Phase 2b trial in 3rd-line follicular lymphoma (FL) patients, refractory to RTX/anti-CD20 based treatments, as a first-to-market NHL indication based on compelling clinical data from earlier clinical studies. The company is also investigating the potential of Betalutin® in earlier lines of treatment for FL and in other significant NHL types.

Betalutin® has been granted Fast Track designation in the US for the treatment of FL after at least two prior systemic therapies and Orphan Drug designation for FL in the US and Europe. Betalutin® has also been granted Fast Track designation in the US and Orphan Drug designation in Europe for relapsed/refractory (R/R) marginal zone lymphoma (MZL).

Beyond Betalutin®, the company intends to leverage its R&D expertise and proprietary platforms to evaluate opportunities with other CD37-targeting immunotherapies across haematological cancers and immune diseases.

[1]*Abdollahi, S., et al., The Impact of Rituximab Resistance on Overall Survival Rate in Low-Grade Follicular Lymphoma. Blood, 2008. 112(11): p. 3783-3783*

Operational review

During 2021, Nordic Nanovector has continued to enrol patients into the PARADIGME Phase 2b trial for Betalutin® and is nearing the target for completing enrolment into this pivotal study – this will represent a key milestone for the company and is expected to allow the company to read out preliminary three-month data during H2'2022.

As of 28 February 2022, 106 of a targeted 120 evaluable patients have been enrolled into the trial. Patients have been enrolled at sites in Europe, Asia and in the US/Canada.

In January 2022, the company revised the timeline for the preliminary data readout following a review of the rate of patient recruitment and discussions with its clinical advisors that also considered the continuing impact from the COVID pandemic.

As this milestone and the subsequent data readout approaches, the company is intensifying its efforts to complete recruitment and continuing to drive the implementation of targeted initiatives to sustain patient enrolment and mitigate COVID restrictions.

The company is preparing for a successful outcome to PARADIGME and is conducting further activities, such as qualification of its manufacturing process in the CMC (Chemistry, Manufacturing and Controls) space, to support a regulatory filing.

The company is also initiating the preparatory activities for the confirmatory Phase 3 trial, the start of which is required upon submission of the BLA (Biologics License Application).

In addition, the company continues to execute its business development and partnering strategy to enable the full potential of Betalutin® in NHL to be realised.

Management Changes

On 20 September, Erik Skullerud joined Nordic Nanovector as the company's Chief Executive Officer (CEO). Mr Skullerud joined the company from Element Consulting GmbH, a globally focused advisory and consultancy specializing in the life science industry where he was co-founder and managing partner.

Prior to establishing Element Consulting, Mr Skullerud spent more than 25 years in the biopharma industry with increasing responsibility in global sales and marketing management roles. This included more than 15 years at Amgen, where his most recent role was as Marketing Director Europe Oncology/Hematology. Prior to that, he worked for Bayer Pharma for seven years, most recently as Product Group Manager for Cardiovascular/Diabetes Scandinavia.

Mr Skullerud has launched numerous highly innovative products in therapeutic areas such as oncology, haematology, cardiology, and nephrology and he has significant business management exposure to EU, Asian and US markets. As a consultant, he has worked with some of the world's top pharma and biotech companies as well as small, highly specialised start-ups on projects ranging from corporate strategy, through early to mid-stage launch and commercialization to late-stage life cycle projects.

On 8 November, Pierre Dodion MD was appointed Chief Medical Officer. Dr Dodion has over 30 years' experience in the biopharmaceutical industry, spent mostly in the oncology and haematology areas. He brings deep clinical development and medical affairs expertise and has provided strategic insight and overseen multiple clinical trials. Furthermore, Dr Dodion contributed to the global launches of several products, including Sutent at Pfizer, Femara at Novartis and two additional oncology products at Aventis.

Dr Dodion joined Nordic Nanovector from Immunooncology Partners, a consultancy he founded to support biotech companies in clinical development, medical affairs and business development activities. In this role, he has acted as a consultant for Nordic Nanovector since April 2021, advising on Betalutin®'s clinical development.

On 16 December, the company announced the appointment of Sandra Jonsson, PhD, MBA as Chief Operating Officer. Dr Jonsson takes over from Marco Renoldi, MD, who is retiring from the role but will remain as a consultant to the company.

Dr Jonsson is a results-driven international Life Science executive, with >15 years of cross-functional experience in global pharmaceutical and biotechnology companies. She has a proven track record of strategy & operations, portfolio management, leading on M&A integrations and executing corporate transformations as well as significant launch experience in the rare diseases and oncology areas.

Dr Jonsson joined Nordic Nanovector from Alexion Pharmaceuticals, at which she was Senior Director, Commercial International (prior to its $39 billion acquisition by AstraZeneca in 2021).

Initiative to improve readiness for radioligand therapy in lymphoma

In November, Nordic Nanovector announced that it is supporting an independent government affairs project* led by The Health Policy Partnership (HPP), a specialist health policy research organisation. Within this project, an international framework (the Radioligand Therapy Readiness Assessment Framework) has been assembled to assess health system readiness for the use of radioligand therapy/radioimmunotherapy and to identify policy changes that could facilitate appropriate integration of this innovative cancer treatment modality.

*www.radioligandtherapy.com/

The framework enables detailed analysis of a healthcare system and helps to identify areas that clinicians, researchers, patient advocates and policymakers could change to improve readiness for radioligand therapies and enable their appropriate integration into routine cancer care.

The project was developed by HPP working with an international expert panel of nuclear medicine and oncology/haematology experts as well as representatives from patient advocacy organizations.

CAR-T cell therapy collaboration with University of Pennsylvania

In October, Nordic Nanovector announced it had entered a research collaboration with the Penn Center for Innovation at the University of Pennsylvania ("UPenn") to generate a CD37-targeting CAR-T cell approach as a potential treatment for patients with B-cell malignancies.

The collaboration aims to combine Nordic Nanovector's expertise around CD37, a protein present on the surface of B-cell tumour cells, and the world-leading expertise in CAR-T cell therapies at UPenn. Specifically, researchers at UPenn will look to combine CD37-targeting molecules (antibodies and antibody fragments) and linkers provided by Nordic Nanovector with the proprietary CAR-T technologies at UPenn, including its proprietary universal immune receptor, which can direct CAR-T cells against multiple tumour associated antigens.

Nordic Nanovector will have an option to license exclusive worldwide rights to any CD37-targeting CAR-T cells that result from the collaboration for further development.

R&D Day hosted in November

On 30 November Nordic Nanovector hosted an R&D Day highlighting the company's strategy for building value from Betalutin® and its pipeline of broader therapeutic opportunities targeting CD37. At the virtual meeting, the company's leaders explored:

- the strategic vision for Nordic Nanovector beyond the pivotal Phase 2b PARADIGME trial for Betalutin®
- the planned expansion of the Betalutin® clinical programme for earlier line treatment of FL and expansion to other NHL subtypes such as diffuse large B-cell lymphoma (DLBCL).
- how targeted radioimmunotherapy can be integrated into NHL care pathways
- progress being made in preparing the CMC component essential for the BLA of Betalutin®
- the rationale behind the company's focus on CD37 as a target, and the emerging opportunities for product development and value creation within its pipeline, including:
    - Humalutin®, a radioimmunotherapy candidate based on a chimeric anti-CD37 antibody conjugated to lutetium-177 for NHL,
    - Alpha37, an alpha-emitting radioimmunotherapy candidate based on a chimeric anti-CD37 antibody conjugated to lead-212, currently being explored with partner Oranomed for relapsed refractory chronic lymphocytic leukaemia,
    - A fully humanized anti-CD37 antibody with potential in haematological cancers and autoimmune diseases, and
    - A CD37 DOTA CAR-T cell opportunity in haematological cancers, which was recently the subject of a research collaboration with the University of Pennsylvania (as noted above)

Dr Leo I. Gordon, a KOL in lymphoma and Abby and John Friend Professor of Cancer Research at the Northwestern University Feinberg School of Medicine, also discussed the remaining unmet medical needs in relapsed FL, particularly in elderly and frail populations, and looked at the potential role of next generation radioimmunotherapies in addressing these challenges.

The full R&D Day presentation is available to view at: nordicnanovector.com/investors-and-media/reports-and-presentations/presentations

Successful Private Placements and Repair Offering

In February and April 2021, respectively, the company successfully completed a Private Placement and oversubscribed Repair Offering, raising a total of approximately NOK 422 million (equivalent to approximately USD 49.7 million) in gross proceeds.

Post the period end in January 2022, the company announced the completion of a new Private Placement that raised further gross proceeds of NOK 250 million.

A subsequent Repair Offering is currently underway with a subscription period that commenced at 09:00 hours (CET) on 28 February 2022 and expires at 16:30 hours (CET) on 11 March 2022 (the "Subscription Period"). The Subscription Period may not be shortened, but the board of directors may extend the subscription period if this is required by law due to the publication of a supplementary prospectus.

- The Subscription Rights are expected to have an economic value if the company's shares trade above the Subscription Price during the Subscription Period
- The Subscription Rights must be used to subscribe for Offer Shares before the expiry of the Subscription Period on 11 March 2022 at 16:30 hours (CET). Subscription Rights that are not exercised before 16:30 hours (CET) on 11 March 2022 will have no value and will lapse without compensation to the holder
- Allocation of the Offer Shares is expected to take place on or about 14 March 2022
- The payment for the Offer Shares allocated to a subscriber falls due on or about 16 March 2022

The net proceeds of the Private Placement and Repair Offering will be used for the following purposes:

- Preparation of activities required for the regulatory filing of Betalutin® and pre-approval inspections
- Continue the preparatory activities for the confirmatory Phase 3 trial including production of clinical material and preparation for market launch
- General corporate purposes

The proceeds from the Private Placements and Repair Offerings are expected to ensure financing past the Company's important value inflection point targeted for H2'2022 (preliminary 3-month data read out from PARADIGME) and for at least an additional three months into 2023 to enable the company to maximise shareholder value from the PARADIGME clinical trial.

Financial review

The interim consolidated financial statements for Nordic Nanovector Group as of 31 December 2021 have been prepared in accordance with the International Accounting Standard (IFRS) 34 interim financial reporting.

Interim consolidated statement of profit or loss

(Figures in brackets = same period 2020 unless stated otherwise)

Revenues in the fourth quarter of 2021 amounted to NOK 0.0 million (NOK 0.0 million). Revenues for the full year 2021 amounted to NOK 0.0 million (NOK 0.0 million).

Total operating expenses for the quarter came to NOK 133.1 million (NOK 106.8 million). Payroll and related expenses increased to NOK 24.4 million (NOK 17.4 million). The increase is driven by higher imputed costs on the employee share-based payment program and increase in number of employees. Other expenses amounted to NOK 105.7 million during the quarter (NOK 85.7 million). Total operating expenses for the full year of 2021 increased to NOK 442.4 million (NOK 434.2 million). Costs are being driven by clinical and manufacturing development activities to prepare for Biologics License Application (BLA) readiness for Betalutin®.

Research and development (preclinical, clinical, medical affairs, regulatory and CMC activities) expenses accounted for 85 % of total operating expenses in 2021 (84 %).

Operating loss for the quarter was NOK 133.1 million (loss of NOK 106.8 million). Operating loss for the full year of 2021 was NOK 442.4 million (NOK 434.2 million).

Net financial items for the fourth quarter came to negative NOK 0.4 million (negative NOK 3.5 million). Net financial items for the full year amounted to NOK 2.3 million (18.0 million), mainly driven by increased value in NOK of cash deposited in foreign currency and interest on deposits.

Nordic Nanovector's comprehensive loss for the quarter amounted to NOK 134.1 million (loss of NOK 112.1 million), due to the reasons stated above. Comprehensive loss for the full year was NOK 441.7 (NOK 417.6 million).

Financial position

Total assets at 31 December 2021 amounted to NOK 296.7 million, down from NOK 314.6 million at year-end 2020.

Total shareholders' equity at 31 December 2021 was NOK 140.5 million (NOK 178.7 million at year-end 2020), corresponding to an equity ratio of 47.4% (56.8 % at year-end 2020).

Total liabilities at 31 December 2021 were NOK 156.2 million, up from NOK 135.9 million from year-end 2020, mainly driven by contractual liabilities related to the ongoing Betalutin® clinical trial.

Cash flow

Net cash flow from operating activities in the fourth quarter and full year 2021 was negative NOK 88.7 million (negative NOK 65.2 million), and negative NOK 403.5 million (negative 398.2 million), respectively.

Net cash flow from investing activities in the fourth quarter and full year was NOK 0.9 million (NOK 1.4 million) and NOK 0.9 (NOK 1.4 million), respectively.

Net cash flow from financing activities for the fourth quarter was negative NOK 2.9 million (negative NOK 19.3 million). Net cash flow from financing activities for the full year 2021 was NOK 385.1 million (NOK 201.5 million), driven by the private placement and repair issue completed in February and April 2021, respectively.

Exchange rate fluctuations in the fourth quarter and full year 2021 was negative NOK 1.1 million (negative NOK 3.6) and 1.2 million (NOK 18.5 million), respectively.

Cash and cash equivalents amounted to NOK 277.7 million at the end of December 2021, compared to NOK 294.0 million at the end of December 2020 for reasons explained above.

Outlook

Nordic Nanovector is close to completing patient enrolment into PARADIGME and is targeting the read out of preliminary three-month top line data during H2' 2022. Following the most recent private placement, the company's current cash position will support its operations through 2022 and for at least an additional 3 months into 2023. This will enable further preparatory work on the potential Betalutin® BLA filing and planning for commercialisation to be undertaken.

The company believes that, if positive, the PARADIGME trial data could represent a significant value inflection point for the company and its shareholders, confirming Betalutin® as a highly promising new targeted radioimmunotherapy that can address the unmet needs of R/R FL patients.

Meanwhile, the company continues to explore further potential partnerships and opportunities for expanding the market for Betalutin® into other haematological cancers, together with other potential areas for pipeline expansion and collaboration based on CD37-targeting immunotherapies.

Responsibility statement

The Board of Directors and the CEO of Nordic Nanovector ASA have today considered and approved the condensed financial statements for the 12-month period ended 31 December 2021. The full year report has been prepared in accordance with IAS 34 Interim Financial Reporting as endorsed by the EU and additional Norwegian regulations.

We confirm, to the best of our knowledge, that:

- the condensed consolidated financial statements for the 12 months ending 31 December 2021 have been prepared in accordance with applicable financial reporting standards
- the information provided in the financial statements gives a true and fair view of the group's assets, liabilities, financial position and result for the period
- the financial review includes a fair review of significant events during the 12 months of the year and their impact on the financial statements, any major related party transactions, and a description of the principal risk and uncertainties for the remaining twelve months of the year

Oslo, 1st March 2022

The Board of Directors
Nordic Nanovector ASA

_____	_____
Jan H. Egberts Chairman	Jean-Pierre Bizzari Board Member
_____	_____
Rainer Boehm Board Member	Joanna Horobin Board Member
_____	_____
Per Samuelsson Board Member	Karin Meyer Board Member
_____	_____
Solveig Hellebust Board Member	Erik Skullerud CEO

Interim condensed consolidated statement of profit or loss and other comprehensive income
Nordic Nanovector Group

Amounts in NOK 1 000	Note	Fourth Quarter		Full Year	
		2021	2020	2021	2020
Revenues		0	0	0	0
Total revenues		**0**	**0**		**0**
Payroll and related expenses	4, 5	24 354	17 421	91 638	78 301
Depreciation		3 038	3 733	11 371	14 895
Other operating expenses	4, 6	105 700	85 664	339 425	340 965
Total operating expenses		**133 092**	**106 818**	**442 434**	**434 161**
Operating profit (loss)		**-133 092**	**-106 818**	**-442 434**	**-434 161**
Net finance income (expenses)	9	-404	-3 507	2 296	18 000
Loss before income tax		**-133 496**	**-110 325**	**-440 138**	**-416 161**
Income tax		-450	-186	-1 165	-914
Loss for the period		**-133 946**	**-110 511**	**-441 303**	**-417 075**
Other comprehensive income (loss), net of income tax to be reclassified to profit and loss in subsequent periods					
Translation effects		-145	-716	-362	423
Other comprehensive income (loss), net of income tax not to be reclassified to profit and loss in subsequent periods					
Re-measurement gains (losses) on defined benefit plans		-20	-912	-20	-912
Total comprehensive income (loss) for the period		**-134 111**	**-112 139**	**-441 685**	**-417 564**
Loss for the period attributable to owners of the company		-133 946	-110 511	-441 303	-417 075
Total comprehensive income (loss) for the period attributable to owners of the company		-134 111	-112 139	-441 685	-417 564
Earnings (loss) per share					
Basic and diluted earnings (loss) per share in NOK	8	-1.37	-1.39	-4.65	-5.99

The interim financial information has not been subject to audit.

Interim condensed consolidated statement of financial position
Nordic Nanovector Group

Amounts in NOK 1 000	Note	31.12.2021	31.12.2020
ASSETS			
Non-current assets			
Property, plant and equipment		766	1 394
Right-of-use-assets		5 177	4 290
Total non-current assets		**5 943**	**5 684**
Current assets			
Receivables			
Other current receivables	4	13 023	14 951
Total receivables		**13 023**	**14 951**
Cash and cash equivalents		**277 706**	**293 975**
Total current assets		**290 729**	**308 926**
TOTAL ASSETS		**296 672**	**314 610**
SHAREHOLDERS' EQUITY AND LIABILITIES			
Shareholders' equity			
Share capital	7	19 616	15 878
Share premium	7	110 573	118 371
Other paid in capital	5, 6	69 157	61 565
Retained earnings		-58 830	-17 146
Total shareholders' equity		**140 516**	**178 668**
LIABILITIES			
Non-current liabilities			
Lease liability		0	2 356
Net employee defined benefit liabilities		4 461	5 025
Total non-current liabilities		**4 461**	**7 381**
Current liabilities			
Accounts payable		65 960	65 862
Tax payable		1 068	803
Other current liabilities		84 667	61 896
Total current liabilities		**151 695**	**128 561**
Total liabilities		**156 156**	**135 942**
TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES		**296 672**	**314 610**

The interim financial information has not been subject to audit.

Interim condensed consolidated statement of changes in equity
Nordic Nanovector Group

For the period ended 31.12.2021								
Amounts in NOK 1 000	**Note**	**Share capital**	**Share premium**	**Other paid in capital**	**Accumulated losses**	**Trans-lation effects**	**Remeasure-ment gains (losses)**	**Total equity**
Balance at 1 January 2020		**13 229**	**335 336**	**69 025**	**-28 806**	**329**	**-1 105**	**388 008**
Loss for the period					-417 075			-417 075
Other comprehensive income (loss) for the year, net of income tax						423	-912	-489
Total comprehensive income for the period		**0**	**0**	**0**	**-417 075**	**423**	**-912**	**-417 564**
Recognition of share-based payments	5, 6			-7 460				-7 460
Issue of ordinary shares	5, 6	2 646	228 856					231 502
Issue of ordinary shares under share options and RSUs	5, 6, 7	4						4
Share issue costs			-15 821					-15 821
Reclassification of accumulated losses			-430 000		430 000			0
Balance at 31 December 2020		**15 878**	**118 371**	**61 565**	**-15 881**	**752**	**-2 017**	**178 668**
Loss for the period					-441 303			-441 303
Other comprehensive income (loss) for the year, net of income tax						-362	-20	-382
Total comprehensive income for the period		**0**	**0**	**0**	**-441 303**	**-362**	**-20**	**-441 685**
Recognition of share-based payments	5, 6			7 592				7 592
Issue of ordinary shares	5, 6	3 715	418 920					422 636
Issue of ordinary shares under share options and RSUs		22	910					932
Share issue costs			-27 629					-27 629
Reclassification of accumulated losses			-400 000		400 000			0
Balance at 31 December 2021		**19 616**	**110 573**	**69 157**	**-57 184**	**390**	**-2 036**	**140 516**

The interim financial information has not been subject to audit.

Interim condensed consolidated statement of cash flow

Amounts in NOK 1 000	Note	Fourth Quarter		Full Year	
		2021	2020	2021	2020
Cash flow from operating activities					
Loss for the period before income tax		**-133 496**	**-110 325**	**-440 138**	**-416 161**
Adjustments for:					
Interests paid		71	58	414	471
Interest received		-1 064	-1 378	-1 122	-1 590
Share option and PSU expenses employees	5	970	-410	6 313	-8 484
Restricted share units (RSUs) expenses board	6	281	300	1 279	1 024
Taxes paid		-9	-635	-844	-1 068
Depreciation		3 038	3 733	11 371	14 895
Currency (gains) losses not related to operating activities		1 073	3 559	-1 229	-18 490
Changes in working capital and non-cash adjustments		40 425	39 933	20 498	31 197
Net cash flow from operating activities		**-88 711**	**-65 165**	**-403 458**	**-398 206**
Cash flow from investing activities					
Investments in property, plant and equipment and intangible assets		-136	-20	-259	-185
Interests received		1 064	1 378	1 122	1 590
Net cash flow from investing activities		**928**	**1 358**	**863**	**1 405**
Cash flows from financing activities					
Net proceeds from equity issue	7	0	-15 723	395 940	215 684
Payment of principle portion of lease liabilities		-2 873	-3 548	-10 429	-13 751
Interests paid		-71	-58	-414	-471
Net cash flow from financing activities		**-2 944**	**-19 329**	**385 097**	**201 462**
Effects of exchange rate changes on cash and cash equivalents		**-1 073**	**-3 559**	**1 229**	**18 490**
Net change in bank deposits, cash and equivalents		-91 800	-86 695	-16 269	-176 849
Cash and equivalents at beginning of period		369 506	380 670	293 975	470 824
Cash and equivalents at end of period		**277 706**	**293 975**	**277 706**	**293 975**

The interim financial information has not been subject to audit.

Notes to the condensed interim financial statements

Note 1. General information

Nordic Nanovector (the group) consists of Nordic Nanovector ASA and its subsidiaries. Nordic Nanovector ASA ("the company") is a limited company incorporated and based in Oslo, Norway. The address of the registered office is *Kjelsåsveien 168 B, 0884 Oslo.*

The figures in this Fourth Quarter and Full Year Report 2021 report are non-audited figures.

These financial statements were approved for issue by the board of directors on 1 March 2022.

Note 2. Basis for preparation and significant accounting policies

The principal accounting policies applied in the preparation of these financial statements can be found in the group's Annual Report 2020. These policies have been consistently applied in all periods presented. Amounts are in Norwegian kroner (NOK) unless stated otherwise. The functional currency of the group is NOK.

Basis of preparation of the annual accounts

The Nordic Nanovector Group's interim consolidated financial statements have been prepared in accordance with the International Financial Reporting Standards (IFRS), which have been adopted by the EU and are mandatory for financial years beginning on or after 1 January 2021, and Norwegian disclose requirements listed in the Norwegian Accounting Act. The interim consolidated financial statements have been prepared on the historical cost basis, with the exception of receivables and other financial liabilities which are recognised at amortised cost.

Note 3. Critical accounting judgments and key sources of estimation uncertainty

Critical accounting estimates and judgments

Management makes estimates and assumptions that affect the reported amounts of assets and liabilities within the next financial year. Estimates and judgments are evaluated on an on-going basis and are based on historical experience and other factors, including expectations of future events that are considered to be relevant.

In preparing these condensed interim financial statements, the significant judgements made by management in applying the group's accounting policies and the key sources of estimation uncertainty were the same as those applied to the consolidated financial statements for the year ended 31 December 2020.

Note 4. Government grants

Government grants have been recognised in profit or loss as a reduction of the related expenses with the following amounts:

Amounts in NOK 1 000	Fourth Quarter		Full Year	
	2021	2020	2021	2020
Payroll and related expenses	39	387	452	959
Other operating expenses	1 149	1 550	4 725	6 791

Grant's receivable presented as other current receivables in the statement of financial position:

Amounts in NOK 1 000	31.12.2021	31.12.2020
Grant's receivable	4 750	5 750

1) R&D projects have been approved for SkatteFUNN grants for the period 2017 through 2021. For the financial period ended 31 December 2021, the company has recognised NOK 4.8 million compared to NOK 4.8 million for the same period in 2020. The amount was recognised partly as a reduction of payroll and related expenses and partly as a reduction of other operating expenses.

2) Preparations for an IND application for Alpha37 for potential treatment of NHL and chronic lymphocytic leukemia (CLL) are now advancing. In 2019, Nordic Nanovector was granted EUR 0.6 million from Eurostars in funding for this project. For the financial period ended 31 December 2021, the company recognised NOK 0.4 million partly as a reduction of payroll and related expenses and other operating expenses, compared to NOK 3.0 million for the same period in 2020.

Note 5. Employee share incentive programmes

Performance Share Units (PSUs)

The board of directors of Nordic Nanovector ASA decided on 26 March 2021 to grant 1 070 000 PSUs to current and newly hired employees. In addition, on 20 September 2021, 350 000 PSUs was granted the company's new CEO.

Overview of outstanding PSUs

	Year to date 2021	
	Number of PSUs	Weighted average exercise price, NOK
Balance at 01.01.2021	774 750	0.2
Granted during the period	1 420 000	0.2
Exercised during the period	-42 611	0.2
Forfeited	-572 139	0.2
Balance at 31.12.2021	**1 580 000**	**0.2**
Hereof vested PSUs	**0**	**0.2**

For further information about the PSU programme see note 6.3.1 to the company's annual accounts included in the company's annual report for 2020.

Share options

The share option programme was discontinued in 2017 and no options have been granted after 2017, but options granted under the programme will remain valid with its existing terms.

Overview of outstanding options

	Year to date 2021	
	Number of options	Weighted average exercise price, NOK
Balance at 01.01.2021	1 351 967	40.74
Granted during the year	0	0
Exercised during the year	-65 900	15.61
Forfeited	-609 767	41.36
Balance at 31.12.2021	**676 300**	**42.64**
Hereof vested options	**676 300**	**42.64**

For further information about the share option programme see note 6.3.3 to the company's annual accounts included in the company's annual report for 2020.

Note 6. Restricted Stock Units (RSUs)

Allocation of restricted stock units (RSUs) to the board of directors

At the annual general meeting (AGM), the shareholders approved the issuance of restricted stock units ("RSUs") to board members who elect to receive all or parts of their remuneration, for the period from the AGM in 2021 to the AGM in 2022, in the form of RSUs.

The RSUs are non-transferable and each RSU give the right and obligation to acquire one share in the Company at a price of NOK 0.20 per share (corresponding to the nominal value of the shares) subject to satisfaction of the applicable vesting conditions stated in the RSU agreements.

The board members may elect to either (i) receive 100% of the compensation in RSUs, (ii) receive 1/3 of the compensation in cash and 2/3 in RSUs, or (iii) receive 2/3 of the compensation in cash and 1/3 in RSUs. The election made by each board member has been set out in the table below. The number of RSUs to be granted to the members of the board of directors is calculated as the NOK amount of the RSU opted portion of total minimum compensation to the board member, divided by the market price for the Nordic Nanovector share. The market price is calculated as volume weighted average share price 10 trading days prior to the date of the AGM, i.e., NOK 25.68.

Pursuant to the RSU program, the board members have made the following election and hold the following number of RSUs and shares following such election:

Name	Remuneration for the period 2021-2022	Allocation between cash and RSUs	Number of RSUs for the period 2021-2022	Total number of RSUs out standing
Jan H. Egberts	NOK 620 000 [1]	1/3 RSUs	8 047	24 654
Per Samuelsson	NOK 390 000 [2]	100% Cash [3]	0	0
Karin Meyer	NOK 370 000 [5]	1/3 RSUs	4 802	10 181
Joanna Horobin	NOK 370 000 [6]	1/3 RSUs	4 802	4 802
Jean-Pierre Bizzari	NOK 370 000 [7]	1/3 RSUs	4 802	4 802
Rainer Boehm	NOK 350 000 [8]	1/3 RSUs	4 543	15 824
Solveig Hellebust	NOK 350 000 [7]	100% RSUs	13 629	13 629

A total of 40 625 RSUs have thus been allocated following the AGM. The RSUs will vest on 28 April 2022. For further information about the RSU Program see section 6.3.2 to the Company's financial statements for 2020, included in the Company's annual report for 2020 on page 95.

Exercise of restricted stock units

The two US-based board members of Nordic Nanovector ASA, Joanna Horobin and Jean-Pierre Bizzari resolved to settle a total number of 22 860 RSUs that were issued to them in June 2020 after they had elected to receive all or part of their remuneration for the period from the AGM in 2020 to the AGM in 2021 in RSUs. In addition, Hilde Steineger, who did not stand for re-election as board member at the annual general meeting in 2021, resolved to settle a total number of 29 106 RSUs previously issued as remuneration under the RSU-program. Each RSU gives the right to subscribe for one share in the Company at a subscription price of NOK 0.20.

Overview of outstanding RSUs

	Year to date 2021
	Number of RSUs
Balance at 01.01.2021	85 233
Granted during the year	40 625
Exercised during the year	51 966
Forfeited	0
Balance at 31.12.2021	**73 892**
Hereof vested RSUs	**33 267**

For further information about the RSU programme see note 6.3.2 to the company's annual accounts included in the company's annual report for 2020.

Note 7. Share capital and shareholder information

The share capital as at 31 December 2021 is NOK 19 615 676 (31 December 2020: NOK 15 878 122), being 98 078 380 ordinary shares at a nominal value of NOK 0.20. All shares carry equal voting rights.

The change in the number of shares during the period was as follows:	**Note**	**31.12.2021**	**31.12.2020**
Ordinary shares at beginning of the period		**79 390 612**	**66 143 363**
Issue of ordinary shares [1)]		18 577 402	13 228 670
Issue of ordinary shares under options [2)]	5	58 400	0
Issue of ordinary shares under RSUs [3)]	6	51 966	18 579
Ordinary shares at end of the period		**98 078 380**	**79 390 612**

[1] In February 2021 the company raised approximately NOK 361 million in gross proceeds through a private placement of 15 878 122 new shares. The private placement was completed at a subscription price of NOK 22.75 per share, which was determined through an accelerated book-building process. In April 2021 the company raised NOK 61 million in gross proceeds through a repair offering, which increased the company's share capital by NOK 539 856 through the issuance of 2 699 280 new shares.

[2] In June current and former employees exercised 58 400 share options.

[3] In June 2021 two US-based board members resolved to settled 22 860 RSUs. In addition, one former board member resolved to settle a total number of 29 106 RSUs previously issued as remuneration under the RSU-program. To fulfil the Company's obligations under the RSU agreements, the board of directors of the company solved to issue 51 966 new shares at a subscription price of NOK 0.20.

Nordic Nanovector ASA had 11 290 shareholders as of 31 December 2021

	Shareholders	Number of shares	Percentage of total shares
1	Folketrygdfondet	7 819 408	7.97%
2	HealthCap VI L.P.	6 834 095	6.97%
3	Fjarde AP-Fonden	4 000 000	4.08%
4	OM Holding AS	3 762 692	3.84%
5	Nordnet Livsforsikring AS	1 762 596	1.80%
6	Sundt AS	1 640 433	1.67%
7	Ro Invest AS	1 000 000	1.02%
8	Linux Solutions Norge	845 071	0.86%
9	Verdipapirfondet Nordea Kapital	834 968	0.85%
10	Birk Venture AS	800 000	0.82%
11	USB Switzerland AG	793 164	0.81%
12	Nordnet Bank AS	776 159	0.79%
13	Verdipapirfondet Nordea Avkastning	703 480	0.72%
14	Must Invest AS	700 000	0.71%
15	Radiumhospitalets Forskningsstiftelse	624 972	0.64%
16	Danske Bank A/S	606 658	0.62%
17	Sciencons AS	575 000	0.59%
18	Boddco AS	550 000	0.56%
19	Myna AS	549 297	0.56%
20	Inven2 AS	541 247	0.55%
	Total shares for top 20 shareholders	35 719 240	36.42%
	Total shares for other 11 270 shareholders	62 359 140	63.58%
	Total shares (11 290 shareholders)	98 078 380	100.00%

The shares of Nordic Nanovector ASA have been traded on the Oslo Stock Exchange since 23 March 2015.

Note 8. Earnings per share

The calculation of basic and diluted earnings per share attributable to the ordinary shareholders of the parent is based on the following data:

Amounts in NOK	Full Year 2021	Full Year 2020
Loss for the period	-441 303 000	-417 075 000
Average number of outstanding shares during the year	94 818 761	69 574 504
Earnings (loss) per share - basic and diluted	**-4.65**	**-5.99**

Share options and PSUs issued have a potential dilutive effect on earnings per share. No dilutive effect has been recognised as potential ordinary shares only shall be treated as dilutive if their conversion to ordinary shares would decrease earnings per share or increase loss per share from continuing operations. As the company is currently loss-making an increase in the average number of shares would have anti-dilutive effects.

Note 9. Net finance income (expense)

Net finance income (expense) is mainly driven by interests on bank deposits and the currency gain (loss) on cash and cash equivalents in foreign currency.

Amounts in NOK 1 000	Fourth Quarter		Full Year	
	2021	2020	2021	2020
Finance income	337	292	1 219	1 610
Finance expenses	130	118	636	860
Net currency gains (losses) on cash and cash equivalents	-1 073	-3 559	1 229	18 490
Net other currency gains (losses) related to operating items	462	-122	484	-1 239
Net finance income	**-404**	**-3 507**	**2 296**	**18 000**

Finance expenses include interest expenses on lease liabilities.

Note 10. Subsequent events

On 7 January 2022 provided an update on the timeline for PARADIGME. Given the ongoing impact from the SARS-CoV-2 omicron variant on patient recruitment, the Company now anticipates the preliminary three-month data readout from PARADIGME to be reported during the second half of 2022 (previously first half of 2022).

On 19 January the company announced a private placement of new shares. In total 17,857,143 new shares were issued at a subscription price of NOK 14 per share. Following registration of the new share capital pertaining to the private placement, the company has a share capital of NOK 23,187,104.60 divided into 115,935,523 shares, each with a par value of NOK 0.20.

On 14 February 2022 an extraordinary general meeting approved authorisation for a share capital increase related to a Repair Offering by up to NOK 714,285.8.

A subsequent Repair Offering is currently underway with a subscription period that commenced at 09:00 hours (CET) on 28 February 2022 and expires at 16:30 hours (CET) on 11 March 2022 (the "Subscription Period"). The

Subscription Period may not be shortened, but the board of directors may extend the subscription period if this is required by law due to the publication of a supplementary prospectus.

- The Subscription Rights are expected to have an economic value if the Company's shares trade above the Subscription Price during the Subscription Period
- The Subscription Rights must be used to subscribe for Offer Shares before the expiry of the Subscription Period on 11 March 2022 at 16:30 hours (CET). Subscription Rights that are not exercised before 16:30 hours (CET) on 11 March 2022 will have no value and will lapse without compensation to the holder
- Allocation of the Offer Shares is expected to take place on or about 14 March 2022
- The payment for the Offer Shares allocated to a subscriber falls due on or about 16 March 2022

Additional information

Glossary of terms

1L, 2L, 3L: First, second and third line of treatment

ARCHER-1: Name of Nordic Nanovector's combination study; Betalutin® and rituximab

ASH: American Society of Hematology

B-cell: A type of lymphocyte (white blood cell) in the humoral immunity of the body's adaptive immune system. Can be distinguished from other lymphocytes by the presence of a protein on the B-cell's outer surface known as a B cell receptor (BCR). This specialized receptor protein allows a B-cell to bind to a specific antigen**.**

CD20: B-lymphocyte antigen CD20 is an activated-glycosylated phosphoprotein expressed in the surface of all B-cells beginning at the pro-B phase and progressively increasing in concentration until maturity

CD37: B-lymphocyte antigen CD-37 is a protein, a member of the transmembrane 4 superfamily, also known as the tetraspanin superfamily of cell surface antigens

CR: Complete Response

DLBCL: Diffuse Large B-Cell Lymphoma

DoR: Duration of Response

FDA: Food and Drug Administration (US)

FL: Follicular Lymphoma

GMP: Good Manufacturing Practice

Haem-Oncs: Haematologist-oncologist

IND: Investigational New Drug

iNHL: Indolent non-Hodgkin Lymphoma

KOL: Key Opinion Leader

Lilotomab (llo): Betalutin® consists of the radionuclide lutetium-177 conjugated to the B-cell seeking anti-CD37 antibody lilotomab

Lu-177: Radionuclide lutetium-177

mAb: Monoclonal antibody

MBq: Megabecquerel (radioactivity measurement unit)

MZL: Marginal zone lymphoma

NDA: New Drug Application

NHL: Non-Hodgkin's Lymphoma

ODD: Orphan Drug Designation

ORR: Overall Response Rate (CR plus PR)

OS: Overall Survival

PARADIGME: name of Nordic Nanovector's pivotal Phase 2b trial

PD: Progressive Disease

PFS: Progression Free Survival

PR: Partial Response

QoL: Quality of Life

R/R: Relapsed/refractory

RTX: Rituximab

SAB: Scientific Advisory Board

SCT: Stem cell transplant

SD: Stable Disease

T-cell: A type of lymphocyte (white blood cell) that plays a central role in cell-mediated immunity. Can be distinguished from other lymphocytes by the presence of a T-cell receptor (TCR) on the cell surface. They are called T-cells because they mature in the thymus

Financial calendar

Q1 2022 results:	13 May 2022
Q2 2022 results	20 July 2022
Q3 2022 results	10 November 2022

The date, time and location of the presentations will be announced in due course.

In accordance with its corporate disclosure policies, the company has a two-week quiet period ahead of its full year and quarterly results announcements. During the quiet periods, the company will not participate in meetings, seminars or engage with external individuals or groups (including analysts, investors, media).

Investor contact

Contact person:	Malene Brondberg, CFO
Phone:	(+ 44) 7561 431 762
E-mail:	ir@nordicnanovector.com
Web:	www.nordicnanovector.com/investors-and-media

Forward-looking statements

This report contains certain forward-looking statements. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances, since they relate to events and depend on circumstances that will occur in the future and which, by their nature, will have an impact on Nordic Nanovector's business, financial condition and results of operations. The terms "anticipates", "assumes", "believes", "can", "could", "estimates", "expects", "forecasts", "intends", "may", "might", "plans", "should", "projects", "targets", "will", "would" or, in each case, their negative, or other variations or comparable terminology are used to identify forward-looking statements. These forward-looking statements are not historic facts. There are a number of factors that could cause actual results and developments to differ materially from those expressed or implied in the forward-looking statements. Factors that could cause these differences include, but are not limited to, risks associated with implementation of Nordic Nanovector's strategy, risks and uncertainties associated with the development and/or approval of Nordic Nanovector's product candidates, ongoing and future clinical trials and expected trial results, the ability to commercialise Betalutin®, technology changes and new products in Nordic Nanovector's potential market and industry, Nordic Nanovector's freedom to operate (competitors patents) in respect of the products it develops, the ability to develop new products and enhance existing products, the impact of competition, changes in general economy and industry conditions, and legislative, regulatory and political factors. No assurance can be given that such expectations will prove to have been correct. Nordic Nanovector disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

Head office

Nordic Nanovector ASA
Kjelsåsveien 168 B
0884 Oslo
Norway
Phone: (+47) 22 18 33 01
E-mail: mail@nordicnanovector.com

Subsidiary

Nordic Nanovector GmbH
Dammstrasse 19
6300 Zug
Switzerland
Phone: (+47) 22 18 33 01
E-mail: mail@nordicnanovector.com

Subsidiary

Nordic Nanovector Ltd
1 Brassey Road
Old Potts Way
Shrewsbury SY3 7FA
United Kingdom
Phone: (+47) 22 18 33 01
E-mail: mail@nordicnanovector.com

Nordic Nanovector Denmark
Branch of Nordic Nanovector ASA, Norway
Th. Bergs Gade 12
9900 Frederikshavn
Denmark
Phone: (+47) 22 18 33 01
E-mail: mail@nordicnanovector.com

www.nordicnanovector.com

NORDIC NANOVECTOR

About Nordic Nanovector

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers.

Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 26 billion by 2028. Nordic Nanovector retains global marketing rights to Betalutin® and intends to actively participate in the commercialisation of Betalutin® in the US and other major markets.